Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Actym Therapeutics Inc.
Headquarters: Berkeley, CA, United States of America
Website: https://www.actymthera.com/
Year Founded: 2017
Status: Private
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jun 26, 2024
Management Tracks
Arvinas, Frontier name new CFOs
Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,
BioCentury | Apr 25, 2024
Management Tracks
Smart to lead Actym as CEO
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
BioCentury | Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
BioCentury | Oct 27, 2023
Management Tracks
CFO John Kuch to retire from Xencor
Plus: Verastem hires new commercial and regulatory heads, and new CTO at Actym
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Jun 2, 2023
Emerging Company Profile
Actym: programming microbes to treat solid tumors
Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
BioCentury | Nov 11, 2022
Discovery & Translation
S&K’s small molecule TNF inhibitor; plus Actym’s engineered bacteria platform and more
BioCentury’s roundup of translational news
BioCentury | May 14, 2022
Management Tracks
Cherrington to be chair at Actym, Stutz joins as CBO
Plus Krishnan leaves Arcus and updates from Invectys, Sawai and West
BioCentury | Nov 16, 2021
Management Tracks
End of an era at Biogen as R&D head Sandrock readies to retire
Plus: Levin-Allerhand joins Flagship, and updates from Alchemab, Agios, Actym, Gilgamesh and more
Items per page:
1 - 10 of 12